Deals this week: OGD2 Pharma, ORIG3N, Impax Labs

22 June 2016 (Last Updated June 22nd, 2016 18:30)

OGD2 Pharma SAS and Green Cross Lab Cell Corporation, a wholly-owned subsidiary of Green Cross Corporation, have entered a co-development agreement to develop cancer immunotherapy products targeting the OAcGD2 antigen.

Teva Pharma

OGD2 Pharma SAS and Green Cross Lab Cell Corporation, a wholly-owned subsidiary of Green Cross Corporation, have entered a co-development agreement to develop cancer immunotherapy products targeting the OAcGD2 antigen.

Pursuant to the agreement, the two companies will conduct joint research, develop and commercialise the NK-cell therapeutics to target the OAcGD2 antigen using humanised antibody and chimeric antibody receptors (CAR), which fight against the solid tumours.

Regenerative medicine company ORIG3N has entered a partnership with Kangstem Biotech, a developer of stem-cell therapies, to further develop a personalised regenerative medicine.

According to the agreement, ORIG3N will utilise Kangstem Biotech's induced neural stem cells (iNSC) in its disease-modelling platform to develop disease-modelling applications for the advancement of regenerative medicines.

Impax Labs has entered a definitive agreement with Teva Pharmaceuticals and affiliates of Allergan to expand and develop its genetic platform, research and development (R&D) and focus on long-term growth through improved business development strategies.

According to the agreement, Impax Labs will acquire a broad portfolio of generic products, which include solid oral, inhalable, injectable and topical dosages, for a purchase consideration of $586m.

Sullivan & Cromwell LLP and McDermott Will & Emery LLP are acting as legal advisors to Impax Labs, while Greenhill & Co is acting as financial advisor and Kirkland & Ellis LLP is acting as legal advisor to Teva Pharma for the transaction.

"Shanxi C&Y Pharmaceuticals has announced plans to raise $472.36m through the private placement of its shares."

Shanxi C&Y Pharmaceuticals has announced plans to raise $472.36m through the private placement of its shares.

The company plans to invest the funds in the acquisition of Shanxi Powerdone Pharmaceutics CO.Ltd.

F2G Ltd has raised gross proceeds of $60m in a venture financing round led by Sectoral Asset Management and co-led by Novo A/S, Aisling Capital and Brace Pharma Capital, Advent Life Sciences LLP, Novartis venture Funds, Sunstone Capital A/S and Merifin Capital.

The company plans to invest the funds in the further development of novel anti-fungal agents, pipeline products and product approvals.


Image: Impax Labs has entered a definitive agreement with Teva Pharmaceuticals and affiliates of Allergan. Photo: Courtesy of Raysonho.